Celgene Total Assets 2006-2019 | CELG

Celgene total assets from 2006 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Celgene total assets for the quarter ending March 31, 2019 were $37.639B, a 8.92% increase year-over-year.
  • Celgene total assets for 2018 were $35.48B, a 17.71% increase from 2017.
  • Celgene total assets for 2017 were $30.141B, a 7.32% increase from 2016.
  • Celgene total assets for 2016 were $28.086B, a 4.16% increase from 2015.
Celgene Annual Total Assets
(Millions of US $)
2018 $35,480
2017 $30,141
2016 $28,086
2015 $26,964
2014 $17,340
2013 $13,378
2012 $11,734
2011 $10,006
2010 $10,177
2009 $5,389
2008 $4,445
2007 $3,611
2006 $2,736
2005 $1,258
Celgene Quarterly Total Assets
(Millions of US $)
Q1 2019 $37,639
Q4 2018 $35,480
Q3 2018 $34,215
Q2 2018 $33,444
Q1 2018 $34,556
Q4 2017 $30,141
Q3 2017 $31,736
Q2 2017 $30,306
Q1 2017 $28,820
Q4 2016 $28,086
Q3 2016 $26,754
Q2 2016 $26,562
Q1 2016 $25,964
Q4 2015 $26,964
Q3 2015 $27,369
Q2 2015 $17,746
Q1 2015 $17,481
Q4 2014 $17,340
Q3 2014 $16,403
Q2 2014 $15,602
Q1 2014 $12,705
Q4 2013 $13,378
Q3 2013 $13,629
Q2 2013 $11,964
Q1 2013 $11,453
Q4 2012 $11,734
Q3 2012 $11,609
Q2 2012 $10,381
Q1 2012 $10,348
Q4 2011 $10,006
Q3 2011 $9,763
Q2 2011 $10,052
Q1 2011 $9,844
Q4 2010 $10,177
Q3 2010 $6,555
Q2 2010 $6,178
Q1 2010 $5,986
Q4 2009 $5,389
Q3 2009 $5,082
Q2 2009 $4,749
Q1 2009 $4,606
Q4 2008 $4,445
Q3 2008 $4,357
Q2 2008 $4,140
Q1 2008 $3,911
Q4 2007 $3,611
Q3 2007 $3,373
Q2 2007 $3,149
Q1 2007 $2,886
Q4 2006 $2,736
Q3 2006 $1,527
Q2 2006 $1,373
Q1 2006 $1,320
Q4 2005 $1,258
Q3 2005 $1,213
Q2 2005 $1,153
Q1 2005 $1,126
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $63.614B $15.281B
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $108.806B 12.30
Gilead Sciences (GILD) United States $82.919B 10.07
Biogen (BIIB) United States $44.842B 8.51
Vertex Pharmaceuticals (VRTX) United States $44.598B 53.91
Illumina (ILMN) United States $43.100B 49.95
CSL (CSLLY) Australia $35.794B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.576B 15.31
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.088B 15.33
Incyte (INCY) United States $17.271B 70.04
Exact Sciences (EXAS) United States $14.835B 0.00
BioMarin Pharmaceutical (BMRN) United States $14.607B 0.00
SINO PHARMACEUT (SBMFF) China $14.154B 0.00
Seattle Genetics (SGEN) United States $12.140B 0.00
Sarepta Therapeutics (SRPT) United States $11.068B 0.00
Genmab (GNMSF) Denmark $11.046B 56.15
Array BioPharma (ARRY) United States $10.373B 0.00
Galapagos (GLPG) Belgium $9.396B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $8.917B 29.29
Guardant Health (GH) United States $8.158B 0.00
Alnylam Pharmaceuticals (ALNY) United States $8.030B 0.00
Bio-Techne Corp (TECH) United States $7.933B 54.13
Bluebird Bio (BLUE) United States $7.614B 0.00
Exelixis (EXEL) United States $6.419B 16.36
Amarin (AMRN) Ireland $5.979B 0.00
BeiGene (BGNE) Cayman Islands $5.801B 0.00
Ascendis Pharma (ASND) Denmark $4.841B 0.00
Blueprint Medicines (BPMC) United States $4.775B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.762B 0.00
Moderna (MRNA) United States $4.642B 0.00
Horizon Pharma Public (HZNP) Ireland $4.456B 11.48
Repligen (RGEN) United States $4.099B 102.12
Mirati Therapeutics (MRTX) United States $3.821B 0.00
Spark Therapeutics (ONCE) United States $3.720B 0.00
ACADIA Pharmaceuticals (ACAD) United States $3.705B 0.00
China Biologic Products (CBPO) China $3.661B 23.25
Alkermes (ALKS) Ireland $3.651B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.569B 0.00
MorphoSys AG (MOR) Germany $3.528B 0.00
Arena Pharmaceuticals (ARNA) United States $3.064B 6.23
Amicus Therapeutics (FOLD) United States $2.934B 0.00
Immunomedics (IMMU) United States $2.860B 0.00
UniQure (QURE) Netherlands $2.736B 0.00
Medicines (MDCO) United States $2.670B 0.00
Reata Pharmaceuticals (RETA) United States $2.620B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.595B 0.00
MyoKardia (MYOK) United States $2.466B 0.00
Halozyme Therapeutics (HALO) United States $2.370B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $2.357B 0.00
NeoGenomics (NEO) United States $2.277B 149.06
Emergent Biosolutions (EBS) United States $2.269B 19.71
Ligand Pharmaceuticals (LGND) United States $2.233B 18.49
Acceleron Pharma (XLRN) United States $2.230B 0.00
Myriad Genetics (MYGN) United States $2.092B 20.81
Genomic Health (GHDX) United States $2.075B 44.07
Zai Lab (ZLAB) China $2.068B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.044B 0.00
Akcea Therapeutics (AKCA) United States $2.041B 0.00
Denali Therapeutics (DNLI) United States $1.988B 0.00
REGENXBIO (RGNX) United States $1.800B 0.00
Insmed (INSM) United States $1.720B 0.00
Cambrex (CBM) United States $1.514B 19.15
AnaptysBio (ANAB) United States $1.474B 0.00
RA PHARMCTL INC (RARX) United States $1.418B 0.00
Fate Therapeutics (FATE) United States $1.393B 0.00
Innoviva (INVA) United States $1.361B 3.76
Sangamo Therapeutics (SGMO) United States $1.338B 0.00
Alector (ALEC) United States $1.298B 0.00
Athenex (ATNX) United States $1.278B 0.00
Coherus BioSciences (CHRS) United States $1.226B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.185B 0.00
Editas Medicine (EDIT) United States $1.174B 0.00
Epizyme (EPZM) United States $1.156B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.032B 0.00
Cara Therapeutics (CARA) United States $1.030B 0.00
Codexis (CDXS) United States $1.011B 0.00
Twist Bioscience (TWST) United States $0.982B 0.00
ANI Pharmaceuticals (ANIP) United States $0.973B 17.25
Zymeworks (ZYME) Canada $0.952B 0.00
Momenta Pharmaceuticals (MNTA) United States $0.947B 0.00
Principia Biopharma (PRNB) United States $0.921B 0.00
Adverum Biotechnologies (ADVM) United States $0.891B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.884B 0.00
Retrophin (RTRX) United States $0.879B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Vericel (VCEL) United States $0.822B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.820B 0.00
WAVE Life Sciences (WVE) Singapore $0.794B 0.00
Arvinas (ARVN) United States $0.789B 0.00
Intellia Therapeutics (NTLA) United States $0.782B 0.00
Precision BioSciences (DTIL) United States $0.701B 0.00
Zealand Pharma (ZEAL) Denmark $0.692B 8.08
Vanda Pharmaceuticals (VNDA) United States $0.688B 32.47
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Intra-Cellular Therapies (ITCI) United States $0.652B 0.00
Cytokineticsorporated (CYTK) United States $0.643B 0.00
Cellectis S.A (CLLS) France $0.634B 0.00
Heska (HSKA) United States $0.622B 63.66
Autolus Therapeutics (AUTL) United Kingdom $0.612B 0.00
DBV Technologies S.A (DBVT) France $0.600B 0.00
Stemline Therapeutics (STML) United States $0.588B 0.00
Clovis Oncology (CLVS) United States $0.580B 0.00
Anika Therapeutics (ANIK) United States $0.577B 19.72
Lexicon Pharmaceuticals (LXRX) United States $0.561B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.560B 0.00
Revance Therapeutics (RVNC) United States $0.554B 0.00
CytomX Therapeutics (CTMX) United States $0.527B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
MiMedx (MDXG) United States $0.503B 0.00
Mesoblast (MESO) Australia $0.494B 0.00
PHARMA MAR SA (PHMMF) Spain $0.452B 0.00
UROGEN PHARMA (URGN) United States $0.438B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.437B 0.00
Puma Biotechnology (PBYI) United States $0.394B 0.00
Prothena (PRTA) Ireland $0.393B 0.00
AC Immune SA (ACIU) Switzerland $0.378B 24.35
PDL BioPharma (PDLI) United States $0.376B 8.97
Biofrontera AG (BFRA) Germany $0.373B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Arcus Biosciences (RCUS) United States $0.364B 0.00
Gritstone Oncology (GRTS) United States $0.361B 0.00
Starpharma Holdings (SPHRY) Australia $0.360B 0.00
Bellus Health (BLUSF) Canada $0.358B 0.00
Scholar Rock Holding (SRRK) United States $0.345B 0.00
Avid Bioservices (CDMO) United States $0.343B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.342B 0.00
Merus (MRUS) Netherlands $0.341B 0.00
BioDelivery Sciences (BDSI) United States $0.341B 0.00
Albireo Pharma (ALBO) United States $0.340B 0.00
Acorda Therapeutics (ACOR) United States $0.332B 5.85
Agenus (AGEN) United States $0.330B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.330B 0.00
Prometic Life Sciences (PFSCD) Canada $0.322B 0.00
Kadmon Holdings (KDMN) United States $0.321B 0.00
Theratechnologies (THERF) Canada $0.320B 0.00
Sorrento Therapeutics (SRNE) United States $0.319B 0.00
Syros Pharmaceuticals (SYRS) United States $0.314B 0.00
Protagonist Therapeutics (PTGX) United States $0.307B 0.00
Senesco Technologies (ELOX) United States $0.297B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.295B 0.00
Cellular Biomedicine (CBMG) United States $0.277B 0.00
Inovio Pharmaceuticals (INO) United States $0.274B 0.00
Kindred Biosciences (KIN) United States $0.264B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.258B 0.00
Sutro Biopharma (STRO) United States $0.256B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.246B 0.00
PHASEBIO PHARMA (PHAS) United States $0.246B 0.00
ChromaDex (CDXC) United States $0.245B 0.00
Kamada (KMDA) Israel $0.239B 9.28
Dynavax Technologies (DVAX) United States $0.238B 0.00
Geron (GERN) United States $0.229B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.225B 0.00
ADMA Biologics Inc (ADMA) United States $0.224B 0.00
Athersys (ATHX) United States $0.213B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.202B 0.00
Five Prime Therapeutics (FPRX) United States $0.202B 0.00
MannKind (MNKD) United States $0.201B 0.00
Mersana Therapeutics (MRSN) United States $0.200B 0.00
Cerecor (CERC) United States $0.197B 0.00
Affimed (AFMD) Germany $0.193B 0.00
OSMOTICA PHARM (OSMT) United States $0.184B 0.00
POXEL SA FRANCE (PXXLF) $0.184B 0.00
Abeona Therapeutics (ABEO) United States $0.184B 0.00
Synlogic (SYBX) United States $0.179B 0.00
Enzo Biochem (ENZ) United States $0.174B 0.00
Spero Therapeutics (SPRO) United States $0.174B 0.00
Compugen (CGEN) Israel $0.172B 0.00
Arsanis (XFOR) United States $0.168B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
XOMA (XOMA) United States $0.165B 0.00
Nicox SA (NICXF) France $0.161B 0.00
Cue Biopharma (CUE) United States $0.157B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.156B 0.00
Strongbridge Biopharma (SBBP) United States $0.150B 8.66
Liquidia Technologies (LQDA) United States $0.144B 0.00
Celyad SA (CYAD) Belgium $0.142B 0.00
Alcobra (ARCT) United States $0.141B 0.00
OvaScience (MLND) United States $0.141B 0.00
Adocia (ADOCY) France $0.140B 0.00
Windtree Therapeutics (WINT) United States $0.138B 0.00
Dyadic (DYAI) United States $0.136B 0.00
TOCAGEN INC (TOCA) United States $0.135B 0.00
Northwest Biotherapeutics (NWBO) United States $0.130B 0.00
Seres Therapeutics (MCRB) United States $0.127B 0.00
Aptinyx (APTX) United States $0.125B 0.00
NantKwest (NK) United States $0.121B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.114B 0.00
Aduro Biotech (ADRO) United States $0.114B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.110B 0.00
Novavax (NVAX) United States $0.108B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.108B 0.00
Verastem (VSTM) United States $0.106B 0.00
Checkpoint Therapeutics (CKPT) United States $0.104B 0.00
Menlo Therapeutics (MNLO) United States $0.103B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.103B 0.00
Catalyst Biosciences (CBIO) United States $0.099B 0.00
Arbutus Biopharma (ABUS) Canada $0.098B 0.00
SESEN BIO, INC (SESN) United States $0.098B 0.00
Trevena (TRVN) United States $0.094B 0.00
Fortress Biotech (FBIO) United States $0.089B 0.00
Pluristem Therapeutics (PSTI) Israel $0.088B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.087B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.084B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.082B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.080B 0.00
Unum Therapeutics (UMRX) United States $0.079B 0.00
VBI Vaccines (VBIV) United States $0.079B 0.00
AquaBounty Technologies (AQB) United States $0.078B 0.00
Curis (CRIS) United States $0.076B 0.00
Selecta Biosciences (SELB) United States $0.076B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.071B 0.00
Idera Pharmaceuticals (IDRA) United States $0.071B 0.00
Applied Genetic Technologies (AGTC) United States $0.071B 38.80
VTv Therapeutics (VTVT) United States $0.070B 0.00
Signal Genetics (MGEN) United States $0.070B 0.00
Orgenesis (ORGS) United States $0.067B 0.00
Oncobiologics (OTLK) United States $0.064B 0.00
Alimera Sciences (ALIM) United States $0.062B 0.00
Antibe Therapeutics (ATBPF) Canada $0.061B 0.00
ARAVIVE, INC (ARAV) United States $0.060B 0.00
NewLink Genetics (NLNK) United States $0.060B 0.00
Organovo Holdings (ONVO) United States $0.060B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.058B 0.00
Prima BioMed (IMMP) Australia $0.057B 0.00
AIT Therapeutics (XAIR) United States $0.057B 0.00